Socazolimab combined with carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis in China
At China's WTP threshold, socazolimab combined with chemotherapy is not cost-effective versus chemotherapy alone for ES-SCLC.
Authors
- LongXun Zhu
- PanFeng Feng
- Shaoqing Zhan
- Yong Chen
- Lian Tang
Institutions
- Xuzhou Medical College (CN)
- Nantong University (CN)
- Affiliated Hospital of Nantong University (CN)
- Second People's Hospital of NanTong (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1371/journal.pone.0339663
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Jiangsu Pharmaceutical Association
- Nanjing Medical University